MindMaze Therapeutics is a pioneering Swiss biopharmaceutical and neurotechnology company based in Geneva. Formed in 2025, it unites innovative expertise in precision medicine, focusing on neurology and rare diseases through its advanced MindMaze neurotherapeutics platform. The company is dedicated to transforming clinical outcomes for patients affected by neurological disorders, such as stroke and Parkinson's disease, utilizing evidence-based therapies delivered via proprietary software and hardware that incorporates wearable technology.

With a substantial investment exceeding USD 350 million, MindMaze has developed its suite of solutions, including MindMotion GO, MindPod, and various other devices that support both in-clinic and at-home therapeutic practices. The company leads in research and innovation, creating a robust pipeline that addresses conditions like spinal cord injury and multiple sclerosis. Partnering with major pharmaceutical firms, MindMaze aims to enhance recovery and quality of life by integrating advanced technologies and collaborative clinical approaches, solidifying its role as a leader in neuroscience and patient care innovation.